Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188253 | 0.73 | — | — | |
| SCHEMBL6467748 | 0.64 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL682268 | 0.64 | — | — | |
| SCHEMBL1712697 | 0.63 | CHRM2 (0.34) | MEN1KMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL25097445 | 0.62 | MMP1 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL598564 | 0.62 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL2640946 | 0.62 | MEN1 (0.32) | MEN1KMT2ACHRM1CHRM3 | |
| SCHEMBL12928689 | 0.62 | CHRM2 (0.32) | MEN1KMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL21789490 | 0.60 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL25954787 | 0.60 | CHRM2 (0.33) | MEN1KMT2ACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | HTR2C, HTR3A, HTR3C | MEN1 2548/4885KMT2A 2718/4885CHRM2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.